Seelos Announces Issuance of a New Patent and an Additional Notice of Allowance in Japan for Intranasal Racemic Ketamine (SLS-002)

Rhea-AI Summary

Seelos Therapeutics, Inc. (Nasdaq: SEEL) announced the issuance of a new patent (Japanese patent number 6722453) covering SLS-002, aimed at treating anxiety from phobic disorders such as Specific Phobia and Social Phobia. Additionally, the company received a Notice of Allowance for another patent application (Japanese patent number 2018-124196) that covers SLS-002's use in preventing anxiety before medical or dental procedures. These developments strengthen Seelos's intellectual property portfolio in the CNS disorder therapeutic area.

Positive

• Issuance of a new patent in Japan covering SLS-002 for treating anxiety in phobic disorders.
• Notice of Allowance for SLS-002 to prevent anxiety prior to medical or dental procedures.

Negative

• None.

NEW YORK, Sept. 14, 2020 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that it has received an issued patent from the Japanese Patent Office (Japanese patent number 6722453) covering SLS-002 titled: ANXIOLYTIC COMPOSITION, FORMULATION AND METHOD OF USE.  The issued claims cover a formulation and method of using SLS-002 to treat patients experiencing anxiety due to phobic disorders such as: Specific Phobia, Agoraphobia, and Social Phobia.

Additionally, Seelos has received a Notice of Allowance from the Japanese Patent Office (Japanese patent application number 2018-124196) covering SLS-002 titled: ANXIOLYTIC COMPOSITION, FORMULATION AND METHOD OF USE.  The allowed claims cover a formulation and method of using SLS-002 to prevent anxiety in patients prior to medical or dental procedures. 

Contact Information:
Anthony Marciano
Head of Corporate Communications
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Ave., 12th Fl
New York, NY 10022
(646) 293-2136
anthony.marciano@seelostx.com 
www.seelostherapeutics.com
https://twitter.com/seelostx
https://www.linkedin.com/company/seelos

View original content to download multimedia:http://www.prnewswire.com/news-releases/seelos-announces-issuance-of-a-new-patent-and-an-additional-notice-of-allowance-in-japan-for-intranasal-racemic-ketamine-sls-002-301129742.html

SOURCE Seelos Therapeutics, Inc.

FAQ

What is the significance of Seelos Therapeutics' new patent for SLS-002?

The new patent (Japanese patent number 6722453) protects the formulation and method of using SLS-002 to treat anxiety related to phobic disorders.

How does the Notice of Allowance affect Seelos Therapeutics?

The Notice of Allowance grants Seelos potential protection for using SLS-002 to prevent anxiety before medical or dental procedures, enhancing their market position.

What disorders does SLS-002 target according to the recent press release?

SLS-002 targets anxiety associated with Specific Phobia, Agoraphobia, and Social Phobia.

When was the press release from Seelos Therapeutics issued?

The press release was issued on September 14, 2020.

What is the stock symbol for Seelos Therapeutics?

The stock symbol for Seelos Therapeutics is SEEL.